International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 54

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 54

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 54

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acidum salclobuzicum

salclobuzic acid — 4-(4-chloro-2-hydroxybenzamido)butanoic acid

acide salclobuzique — acide 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoïque

ácido salclobúzico — ácido 4-[(4-cloro-2-hidroxibenzoil)amino]butanoico

$C_{11}H_{12}ClNO_4$



ancrivirocum

ancriviroc — 3-({4-[(*Z*)-(4-bromophenyl)(ethoxyimino)methyl]-4'-methyl-[1,4'-bipiperidin]-1'-yl}carbonyl)-2,4-dimethylpyridine-1-oxide

ancriviroc — 4-[(*Z*)-(4-bromophényl)(éthoxyimino)méthyl]-1'-[(2,4-diméthyl-1-oxydopyridin-3-yl)carbonyl]-4'-méthyl-1,4'-bipipéridinyle

ancriviroc — 4-[(*Z*)-(4-bromofenil)(etoxiimino)metil]-1'-[(2,4-dimetil-1-oxidopiridin-3-il)carbonil]-4'-metil-1,4'-bipipéridinilo

$C_{28}H_{37}BrN_4O_3$



aplindorum

aplindore — (2*S*)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8*H*-1,4-dioxino=[2,3-*e*]indol-8-one

aplindore — (2*S*)-2-[(benzylamino)méthyl]-2,3,7,9-tétrahydro-8*H*-1,4-dioxino=[2,3-*e*]indol-8-one

aplindor — (2*S*)-2-[(bencilamino)metil]-2,3,7,9-tetrahidro-8*H*-1,4-dioxino=[2,3-*e*]indol-8-ona

$C_{18}H_{18}N_2O_3$



atilmotinum

atilmotin — *N*-[(2*S*)-3-phenyl-2-(trimethylazaniumyl)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide

atilmotine — *N*-[(2*S*)-3-phényl-2-(triméthylammonio)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phénylalanyl-L-thréonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide

atilmotina — *N*-[(2*S*)-3-fenil-2-(trimetilamonio)propanoil]-L-valil-L-prolil-L-isoleucil-L-fenilalanil-L-treonil-L-tirosilglicil-L-glutamil-L-leucil-L-glutaminil-D-arginil-L-leucil-L-lisinamida

$C_{86}H_{134}N_{20}O_{19}$



Leu—Gln—D-Arg—Leu—Lys—NH_2

avanafilum

avanafil — 4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

avanafil — 4-[(3-chloro-4-méthoxybenzyl)amino]-2-[(2*S*)-2-(hydroxyméthyl)=pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylméthyl)pyrimidine-5-carboxamide

avanafilo — 4-[(3-cloro-4-metoxibencil)amino]-2-[(2*S*)-2-(hidroximetil)pirrolidin-1-il]-*N*-(pirimidin-2-ilmetil)pirimidina-5-carboxamida

$C_{23}H_{26}ClN_7O_3$



balicatibum

balicatib — *N*-{1-[(cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propylpiperazin-1-yl)benzamide

balicatib — *N*-[1-[(cyanométhyl)carbamoyl]cyclohexyl]-4-(4-propylpipérazin-1-yl)benzamide

balicatib — *N*-[1-[(cianometil)carbamoil]ciclohexil]-4-(4-propilpiperazin-1-il)benzamida

$C_{23}H_{33}N_5O_2$



becatecarinum

becatecarin — 1,11-dichloro-6-[2-(diethylamino)ethyl]-12-(4-*O*-methyl-β-D-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo=[3,4-*c*]carbazole-5,7(6*H*)-dione

bécatécarine — 1,11-dichloro-6-[2-(diéthylamino)éthyl]-12-(4-*O*-méthyl-β-D-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo=[3,4-*c*]carbazole-5,7(6*H*)-dione

becatecarina — 1,11-dicloro-6-[2-(dietilamino)etil]-12-(4-*O*-metil-β-D-glucopiranosil)-12,13-dihidro-5*H*-indolo[2,3-*a*]pirrolo[3,4-*c*]carbazol-5,7(6*H*)-diona

$C_{33}H_{34}Cl_2N_4O_7$



becocalcidiolum

becocalcidiol (1*R*,3*R*)-4-(2-{(1*R*,3a*S*,7a*R*)-1-[(2*S*)-butan-2-yl]-7a-methyloctahydro-4*H*-inden-4-ylidene}ethylidene)-2-methylidenecyclohexane-1,3-diol

bécocalcidiol (1*R*,3*R*)-2-méthylidène-5-[(2*E*)-2-[(1*R*,3a*S*,7a*R*)-7a-méthyl-1-[(1*S*)-1-méthylpropyl]octahydro-4*H*-indén-4-ylidène]éthylidène]= cyclohexane-1,3-diol

becocalcidiol (1*R*,3*R*)-2-metilideno-5-[(2*E*)-2-[(1*R*,3a*S*,7a*R*)-7a-metil-1-[(1*S*)-1-metilpropil]octahidro-4*H*-inden-4-ilideno]etilideno]= ciclohexano-1,3-diol

$C_{23}H_{36}O_2$



bemotrizinolum

bemotrizinol 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis={5-[(2-ethylhexyl)oxy]phenol}

bémotrizinol 2,2'-[6-(4-méthoxyphényl)-1,3,5-triazine-2,4-diyl]bis=[5-[(2-éthylhexyl)oxy]phénol]

bemotrizinol 2,2'-[6-(4-metoxifenil)-1,3,5-triazina-2,4-diil]bis[5-[(2-etilhexil)=oxi]fenol]

$C_{38}H_{49}N_3O_5$



besilesomabum

besilesomab	immunoglobulin G1, anti-(human CEA (carcinoembryonic antigen)-related antigen) (mouse monoclonal BW 250/183 heavy chain), disulfide with mouse monoclonal BW 250/183 κ-chain, dimer
bésilésomab	immunoglobuline G1, anti-(molécules de l'adhésion cellulaire, antigènes carcinoembryonaires humains (CEA ou CD66)), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris BW 250/183
besilesomab	inmunoglobulina G1, anti-(moléculas de adhesión celular, antígenos carcinoembrionarios humanos (CEA o CD66)), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal de ratón BW 250/183

bisoctrizolum

bisoctrizole	2,2'-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol]
bisoctrizole	2,2'-méthylènebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tétraméthylbutyl)phénol]
bisoctrizol	2,2'-metilenobis[6-(2*H*-benzotriazol-2-il)-4-(1,1,3,3-tetrametilbutil)=fenol]

$C_{41}H_{50}N_6O_2$



canfosfamidum

canfosfamide	*N*-γ-L-glutaminyl-3-(2-{bis[bis(2-chloroethyl)amino]=phosphoryl}ethanesulfonyl)-L-alanyl-(2*R*)-2-phenylglycine
canfosfamide	acide (2*S*)-2-amino-5-[[(1*R*)-1-[[[2-[[bis[bis(2-chloroéthyl)amino]=phosphinoyl]oxy]éthyl]sulfonyl]méthyl]-2-[[(*R*)-carboxyphénylméthyl]=amino]-2-oxoéthyl]amino]-5-oxopentanoïque
canfosfamida	ácido (2*S*)-2-amino-5-[[(1*R*)-1-[[[2-[[bis[bis(2-cloroetil)amino]=fosfinoil]oxi]etil]sulfonil]metil]-2-[[(*R*)-carboxifenilmetil]amino]-2-oxoetil]amino]-5-oxopentanoico

$C_{26}H_{40}Cl_4N_5O_{10}PS$



ceftobiprolum

ceftobiprole	(6*R*,7*R*)-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-8-oxo-3-[(*E*){(3'*R*)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}=methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftobiprole	acide (6*R*,7*R*)-7-[[(2*Z*)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-8-oxo-3-[(*E*)-[(3'*R*)-2-oxo-1,3'-bipyrrolidinyl-3-ylidène]méthyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique
ceftobiprol	ácido (6*R*,7*R*)-7-[[(2*Z*)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetil]amino]-8-oxo-3-[(*E*)-[(3'*R*)-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

$C_{20}H_{22}N_8O_6S_2$



ceftobiprolum medocarilum

ceftobiprole medocaril	(6*R*,7*R*)-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-3-[(*E*){(3'*R*)-1'-[(5-methyl-2-oxo-1,3-dioxol-4-yl)=methoxycarbonyl]-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceftobiprole médocaril	acide (6*R*,7*R*)-7-[[(2*Z*)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-3-[(*E*)-[(3'*R*)-1'-[[(5-méthyl-2-oxo-1,3-dioxol-4-yl)méthoxy]carbonyl]-2-oxo-1,3'-bipyrrolidinyl-3-ylidène]méthyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique
ceftobiprol medocarilo	ácido (6*R*,7*R*)-7-[(2*Z*)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetamido]-3-[(*E*)-[(3'*R*)-1'-[[(5-metil-2-oxo-1,3-dioxol-4-il)metoxi]carbonil]-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

$C_{26}H_{26}N_8O_{11}S_2$



cintredekinum besudotoxum

cintredekin besudotox — toxin hIL13-PE38QQR (plasmid phuIL13-Tx)

cintrédékine bésudotox — [Met^{17},His^{18}]précurseur de l'interleukine-13 humaine-(17-132)-peptide (132→246')-protéine avec la dès-Ala^{365},Asp^{366},Val^{367},Val^{368},Ser^{369},Leu^{370},Thr^{371},Cys^{372},Pro^{373},Val^{374},Ala^{375},Ala^{376},Gly^{377},Glu^{378},Cys^{379},Ala^{380}-[Lys^{246},Ala^{247},Ser^{248},Gly^{249},Gly^{250},Asn^{364},Val^{407},Ser^{515},Gln^{590},Gln^{606},Arg^{613}]exotoxine A (*Pseudomonas aeruginosa*)-(246-613)-peptide

cintredekina besudotox — toxina hIL13-PE38QQR (plásmido phuIL13-Tx)

$C_{2234}H_{3512}N_{650}O_{682}S_{10}$

```
MHSPGPVPPS TALRELIEEL VNITQNQKAP LCNGSMVWSI
NLTAGMYCAA LESLINVSGC SAIEKTQRML SGFCPHKVSA
GQFSSLHVRD TKIEVAQFVK DLLLHLKKLF REGRFNKASG
GPEGGSLAAL TAHQACHLPL ETFTRHRQPR GWEQLEQCGY
PVQRLVALYL AARLSWNQVD QVIRNALASP GSGGDLGEAI
REQPEQARLA LTLAAAESER FVRQGTGNDE AGAANGPADS
GDALLERNYP TGAEFLGDGG DVSFSTRGTQ NWTVERLLQA
HRQLEERGYV FVGYHGTFLE AAQSIVFGGV RARSQDLDAI
WRGFYIAGDP ALAYGYAQDQ EPDARGRIRN GALLRVYVPR
SSLPGFYRTS LTLAAPEAAG EVERLIGHPL PLRLDAITGP
EEEGGRLETI LGWPLAERTV VIPSAIPTDP RNVGGDLDPS
SIPDQEQAIS ALPDYASQPG QPPREDLR
```

davasaicinum

davasaicin — 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-*N*-[3-(3,4-dimethylphenyl)=propyl]acetamide

davasaïcine — 2-[4-(2-aminoéthoxy)-3-méthoxyphényl]-*N*-[3-(3,4-diméthylphényl)=propyl]acétamide

davasaicina — 2-[4-(2-aminoetoxi)-3-metoxifenil]-*N*-[3-(3,4-dimetilfenil)propil]=acetamida

$C_{22}H_{30}N_2O_3$



deferitrinum

deferitrin — (4*S*)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid

déféritrine — acide (+)-(4*S*)-2-(2,4-dihydroxyphényl)-4-méthyl-4,5-dihydrothiazole-4-carboxylique

deferitrina — ácido (+)-(4*S*)-2-(2,4-dihidroxifenil)-4-metil-4,5-dihidrotiazol-4-carboxílico

$C_{11}H_{11}NO_4S$



delmitidum

delmitide — (2*R*)-2-[(2*R*)-2-{(2*R*)-2-[(2*R*)-2-{(2*R*)-2-[(2*R*)-2-(D-arginylamino)=hexanamido]hexanamido}hexanoyl-D-arginylamino]=hexanamido}hexanamido]hexanoylglycyl-D-tyrosinamide

delmitide — D-arginyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoyl-D-arginyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoyl-(2*R*)-2-aminohexanoylglycyl-D-tyrosinamide

delmitida — D-arginil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoil-D-arginil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoil-(2*R*)-2-aminohexanoilglicil-D-tirosinamida

$C_{59}H_{105}N_{17}O_{11}$



deutolperisonum

deutolperisone — 2-methyl-1-{4-([$^2H_3$]methyl)[2,3,5,6-$^2H_4$]phenyl}-3-(piperidin-1-yl)propan-1-one

deutolpérisone — (2*RS*)-2-méthyl-1-(4-($^2H_3$)méthyl(2,3,5,6-$^2H_4$)phényl)-3-(pipéridin-1-yl)propan-1-one

deutolperisona — (2*RS*)-2-metil-1-(4-[$^2H_3$]metil[2,3,5,6-$^2H_4$]fenil)-3-(piperidin-1-il)propan-1-ona

$C_{16}H_{16}{}^{2}H_{7}NO$



and enantiomer
et énantiomère
y enantiómero

efipladibum

efipladib — 4-(3-{5-chloro-2-[2-({[(3,4-dichlorophenyl)methyl]sulfonyl}amino)=ethyl]-1-(diphenylmethyl)-1*H*-indol-3-yl}propyl)benzoic acid

éfipladib — acide 4-[3-[5-chloro-2-[2-[[(3,4-dichlorobenzyl)sulfonyl]amino]éthyl]-1-(diphénylméthyl)-1*H*-indol-3-yl]propyl]benzoïque

efipladib — ácido 4-[3-[5-cloro-2-[2-[[(3,4-diclorobencil)sulfonil]amino]etil]-1-(difenilmetil)-1*H*-indol-3-il]propil]benzoico

$C_{40}H_{35}Cl_3N_2O_4S$



elomotecanum

elomotecan — (5*R*)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methylpiperidin-1-yl)methyl]-1,4,5,13-tetrahydro-3*H*,15*H*-oxepino[3',4':6,7]=indolizino[1,2-*b*]quinoline-3,15-dione

élomotécan — (5*R*)-9-chloro-5-éthyl-5-hydroxy-10-méthyl-12-[(4-méthylpipéridin-1-yl)méthyl]-1,4,5,13-tétrahydro-3*H*,15*H*-oxépino[3',4':6,7]=indolizino[1,2-*b*]quinoléine-3,15-dione

elomotecán — (5*R*)-9-cloro-5-etil-5-hidroxi-10-metil-12-[(4-metilpiperidin-1-il)metil]-1,4,5,13-tetrahidro-3*H*,15*H*-oxepino[3',4':6,7]indolizino=[1,2-*b*]quinolina-3,15-diona

$C_{29}H_{32}ClN_3O_4$



embeconazolum

embeconazole — 4-{(1*E*,3*E*)-4-(*trans*-5-{[(2*R*,3*R*)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]sulfanyl}-1,3-dioxan-2-yl)buta-1,3-dien-1-yl}-3-fluorobenzonitrile

embéconazole — (-)-4-[(1*E*,3*E*)-4-[*trans*-5-[[(1*R*,2*R*)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]sulfanyl]-1,3-dioxan-2-yl]buta-1,3-diényl]-3-fluorobenzonitrile

embeconazol — (-)-4-[(1*E*,3*E*)-4-[*trans*-5-[[(1*R*,2*R*)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-3-(1*H*-1,2,4-triazol-1-il)propil]sulfanil]-1,3-dioxan-2-il]buta-1,3-dienil]-3-fluorobenzonitrilo

$C_{27}H_{25}F_3N_4O_3S$



epoetinum zeta

epoetin zeta — 1-165-erythropoietin (human clone B03XA01), glycoform ζ

époétine zêta — 1-165-érythropoïétine (humaine B03XA01), glycoforme ζ

epoetina zeta — 1-165-eritropoyetina (humana B03XA01), glicoforma ζ

$C_{809}H_{1301}N_{229}O_{240}S_5$

eritoranum

eritoran — 2-deoxy-3-*O*-[(3*R*)-3-methoxydecyl]-6-*O*-methyl-2-(octadec-11-enamido)-4-*O*-phosphono-β-D-glucopyranosyl-(1→6)-3-*O*-decyl-2-deoxy-2-(3-oxotetradecanamido)-α-D-glucopyranose 1-(dihydrogen phosphate)

éritoran — dihydrogénophosphate de 3-*O*-décyl-2-désoxy-6-*O*-[2-désoxy-3-*O*-[(3*R*)-3-méthoxydécyl]-6-*O*-méthyl-2-[(11*Z*)-octadéc-11-énoylamino]-4-*O*-phosphono-β-D-glucopyranosyl]-2-[(3-oxotétradécanoyl)amino]-α-D-glucopyranosyle

eritorán — dihidrógenofosfato de 3-*O*-decil-2-desoxi-6-*O*-[2-desoxi-3-*O*-[(3*R*)-3-metoxidecil]-6-*O*-metil-2-[(11*Z*)-octadec-11-enamido]-4-*O*-fosfono-β-D-glucopiranosil]-2-(3-oxotetradecanamido)-α-D-glucopiranosilo

$C_{66}H_{126}N_2O_{19}P_2$



etalocibum

etalocib	2-(3-{3-[(5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy]propoxy}-2-propylphenoxy)benzoic acid
étalocib	acide 2-[3-[3-[(5-éthyl-4'-fluoro-2-hydroxybiphényl-4-yl)oxy]propoxy]-2-propylphénoxy]benzoïque
etalocib	ácido 2-[3-[3-[(5-etil-4'-fluoro-2-hidroxibifenil-4-il)oxi]propoxi]-2-propilfenoxi]benzoico

$C_{33}H_{33}FO_6$



farampatorum

farampator	5-[(piperidin-1-yl)carbonyl]-2,1,3-benzooxadiazole
farampator	1-(2,1,3-benzoxadiazol-5-ylcarbonyl)pipéridine
farampator	1-(2,1,3-benzoxadiazol-5-ilcarbonil)piperidina

$C_{12}H_{13}N_3O_2$



forodesinum

forodesine	7-(5-amino-1,5-dideoxy-β-D-ribofuranos-1-yl)-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one
forodésine	(-)-7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihydroxy-5-(hydroxyméthyl)pyrrolidin-2-yl]-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one
forodesina	(-)-7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihidroxi-5-(hidroximetil)pirrolidin-2-il]-1,5-dihidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona

$C_{11}H_{14}N_4O_4$



galsulfasum

galsulfase	*N*-acetylgalactosamine 4-sulfatase (human CSL4S-342 cell)
galsulfase	*N*-acétylgalactosamine 4-sulfatase (cellule humaine CSL4S-342)
galsulfasa	*N*-acetilgalactosamina 4-sulfatasa (célula humana CSL4S-342)

$C_{2529}H_{3843}N_{689}O_{716}S_{16}$

AGASRPPHLV	FLLADDLGWN	DVGFHGSRIR	TPHLDALAAG
GVLLDNYYTQ	PLCTPSRSQL	LTGRYQIRTG	LQHQIIWPCQ
PSCVPLDEKL	LPQLLKEAGY	TTHMVGKWHL	GMYRKECLPT
RRGFDTYFGY	LLGSEDYYSH	ERCTLIDALN	VTRCALDFRD
GEEVATGYKN	MYSTNIFTKR	AIALITNHPP	EKPLFLYLAL
QSVHEPLQVP	EEYLKPYDFI	QDKNRHHYAG	MVSLMDEAVG
NVTAALKSSG	LWNNTVFIFS	TDNGGQTLAG	GNNWPLRGRK
WSLWEGGVRG	VGFVASPLLK	QKGVKNRELI	HISDWLPTLV
KLARGHTNGT	KPLDGFDVWK	TISEGSPSPR	IELLHNIDPN
FVDSSPCPRN	SMAPAKDDSS	LPEYSAFNTS	VHAAIRHGNW
KLLTGYPGCG	YWFPPPSQYN	VSEIPSSDPP	TKTLWLFDID
RDPEERHDLS	REYPHIVTKL	LSRLQFYHKH	SVPVYFPAQD
PRCDPKATGV	WGPWM		

glucarpidasum

glucarpidase	recombinant glutamate carboxypeptidase (carboxypeptidase G_2)
glucarpidase	[405-arginine]précurseur de la carboxypeptidase G2 de *Pseudomonas* (RS-16), enzyme à zinc dimérique, glutamate carboxypeptidase
glucarpidasa	glutamato carboxipeptidasa recombinante (carboxipeptidasa G2)

$C_{1950}H_{3157}N_{543}O_{599}S_7$ (monomer)

MRPSIHRTAI AAVLATAFVA GTALAQKRDN VLFQAATDEQ
PAVIKTLEKL VNIETGTGDA EGIAAAGNFL EAELKNLGFT
VTRSKSAGLV VGDNIVGKIK GRGGKNLLLM SHMDTVYLKG
ILAKAPFRVE GDKAYGPGIA DDKGGNAVIL HTLKLLKEYG
VRDYGTITVL FNTDEEKGSF GSRDLIQEEA KLADYVLSFE
PTSAGDEKLS LGTSGIAYVQ VNITGKASHA GAAPELGVNA
LVEASDLVLR TMNIDDKAKN LRFNWTIAKA GNVSNIIPAS
ATLNADVRYA RNEDFDAAMK TLEERAQQKK LPEADVKVIV
TRGRPAFNAG EGGKKLVDKA VAYYKEAGGT LGVEERTGGG
TDAAYAALSG KPVIESLGLP GFGYHSDKAE YVDISAIPRR
LYMARRLIMD LGAGK

iboctadekinum

iboctadekin	a recombinant human interleukin-18 with 157 amino acids
iboctadékine	interleukine-18 humaine recombinante (157 aminoacides)
iboctadekina	interleukina-18 humana recombinante (157 aminoácidos)

$C_{801}H_{1264}N_{212}O_{252}S_{10}$

YFGKLESKLS VIRNLNDQVL FIDQGNRPLF EDMTDSDCRD
NAPRTIFIIS MYKDSQPRGM AVTISVKCEK ISTLSCENKI
ISFKEMNPPD NIKDTKSDII FFQRSVPGHD NKMQFESSSY
EGYFLACEKE RDLFKLILKK EDELGDRSIM FTVQNED

icomucretum

icomucret	(5*Z*,8*Z*,11*Z*,13*E*,15*S*)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
icomucret	acide (5*Z*,8*Z*,11*Z*,13*E*,15*S*)-15-hydroxyicosa-5,8,11,13-tétraénoïque
icomucret	ácido (5*Z*,8*Z*,11*Z*,13*E*,15*S*)-15-hidroxiicosa-5,8,11,13-tetraenoico

$C_{20}H_{32}O_3$



inotuzumabum ozogamicinum

inotuzumab ozogamicin

immunoglobulin G4, anti-(human CD22 (antigen)) (human-mouse monoclonal G544 heavy chain), disulfide with human-mouse monoclonal G544 κ-chain, dimer, conjugate with methyl *N*-{(1*R*,4*Z*,8*S*,13*E*)-8-(4,6-dideoxy-4-{[(4-*S*-{4-[(6-deoxy-3-*O*-methyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl}-4-thio-β-D-*ribo*-hexopyranosyl)oxy]amino}-2-*O*-[4-(*N*-ethylacetamido)-2,4-dideoxy-3-*O*-methyl-α-L-*threo*-pentopyranosyl]-β-D-glucopyranosyloxy)-13-[2-({4-[2-(1-{[4-(4-amino-4-oxobutyl)oxy]phenyl}ethylidene)hydrazinyl]-2-methyl-4-oxobutan-2-yl}disulfanyl)ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl}carbamate

inotuzumab ozogamicine

N-[4-[4-[1-[[3-[[2-[(1*R*,4*Z*,8*S*,13*E*)-8-[[2-*O*-[4-(acétyléthylamino)-2,4-didésoxy-3-*O*-méthyl-α-L-*thréo*-pentopyranosyl]-4,6-didésoxy-4-[[[2,6-didésoxy-4-*S*-[4-[(6-désoxy-3-*O*-méthyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-diméthoxy-2-méthylbenzoyl]-4-thio-β-D-*ribo*-hexopyranosyl]oxy]amino]-β-D-glucopyranosyl]oxy]-1-hydroxy-10-[(méthoxycarbonyl)amino]-11-oxobicyclo[7.3.1]tridéca-4,9-diène-2,6-diyn-13-ylidène]éthyl]disulfanyl]-3-méthylbutanoyl]=diazanylidène]éthyl]phénoxy]butanoyl]immunoglobuline G4, anti-(antigène CD22 humain) dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris G544 humanisé

inotuzumab ozogamicina

N-[4-[4-[1-[[3-[[2-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acetiletilamino)-2,4-didesoxi-3-O-metil-α-L-treo-pentopiranosil]-4,6-didesoxi-4-[[[2,6-didesoxi-4-S-[4-[(6-desoxi-3-O-metil-α-L-manopiranosil)oxi]-3-iodo-5,6-dimetoxi-2-metilbenzoil]-4-tio-β-D-ribo-hexopiranosil]=oxi]amino]-β-D-glucopiranosil]oxi]-1-hidroxi-10-[(metoxicarbonil)=amino]-11-oxobiciclo[7.3.1]trideca-4,9-dieno-2,6-diino-13-ilideno]etil]disulfanil]-3-metilbutanoil]diazanilideno]etil]fenoxi]=butanoil]inmunoglobulina G4, anti-(antigeno CD22 humano) dimero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humanizado de ratón G544

$C_{6518}H_{10002}N_{1738}O_{2036}S_{42}$

Ig-NH_2 = inotuzumab



isalmadolum

isalmadol — 3-{(1*RS*,2*RS*)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenyl 2-hydroxybenzoate

isalmadol — 2-hydroxybenzoate de 3-[(1*RS*,2*RS*)-2-[(diméthylamino)méthyl]-1-hydroxycyclohexyl]phényle

isalmadol — 2-hidroxibenzoato de 3-[(1RS,2RS)-2-[(dimetilamino)metil]-1-hidroxiciclohexil]fenilo

$C_{22}H_{27}NO_4$



and enantiomer
et énantiomère
y enantiómero

ispinesibum

ispinesib — *N*-(3-aminopropyl)-*N*-[(1*R*)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

ispinésib — *N*-(3-aminopropyl)-*N*-[(1*R*)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-méthylpropyl]-4-méthylbenzamide

ispinesib — *N*-(3-aminopropil)-*N*-[(1*R*)-1-(3-bencil-7-cloro-4-oxo-3,4-dihidroquinazolin-2-il)-2-metilpropil]-4-metilbenzamida

$C_{30}H_{33}ClN_4O_2$



levotofisopamum

levotofisopam — (5*S*)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5*H*-2,3-benzodiaxepine

lévotofisopam — (-)-(5*S*)-1-(3,4-diméthoxyphényl)-5-éthyl-7,8-diméthoxy-4-méthyl-5*H*-2,3-benzodiazépine

levotofisopam — (-)-(5*S*)-1-(3,4-dimetoxifenil)-5-etil-7,8-dimetoxi-4-metil-5*H*-2,3-benzodiazepina

$C_{22}H_{26}N_2O_4$



linaprazanum

linaprazan	8-{[(2,6-dimethylphenyl)methyl]amino}-*N*-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxamide
linaprazan	8-[(2,6-diméthylbenzyl)amino]-*N*-(2-hydroxyéthyl)-2,3-diméthylimidazo[1,2-*a*]pyridine-6-carboxamide
linaprazán	8-[(2,6-dimetilbencil)amino]-N-(2-hidroxietil)-2,3-dimetilimidazo=[1,2-a]piridina-6-carboxamida

$C_{21}H_{26}N_4O_2$



morphini glucuronidum

morphine glucuronide	3-hydroxy-17-methyl-4,5α-epoxymorphin-7-en-6α-yl β-D-glucopyranosiduronic acid
glucuronide de morphine	acide β-D-glucopyranosiduronique de 7,8-didéshydro-4,5α-époxy-3-hydroxy-17-méthylmorphinan-6α-yle
glucurónido de morfina	ácido β-D-glucopiranosidurónico de 7,8-dideshidro-4,5α-epoxi-3-hidroxi-17-metilmorfinan-6α-ilo

$C_{23}H_{27}NO_9$



naveglitazarum

naveglitazar — (2*S*)-2-methoxy-3-{4-[3-(4-phenoxyphenoxy)propoxy]phenyl}= propanoic acid

navéglitazar — acide (2*S*)-2-méthoxy-3-[4-[3-(4-phénoxyphénoxy)propoxy]phényl]= propanoïque

naveglitazar — ácido (2*S*)-2-metoxi-3-[4-[3-(4-fenoxifenoxi)propoxi]fenil]propanoico

$C_{25}H_{26}O_6$



omocianinum

omocianine — 2-{(1*E*,3*E*,5*E*)-7-[(2*E*)-3,3-dimethyl-5-sulfonato-1-(2-sulfonatoethyl)-1,3-dihydro-2*H*-indol-2-ylidene]-4-methylhepta-1,3,5-trienyl}-3,3-dimethyl-1-(2-sulfonatoethyl)-3*H*-indolium-5-sulfonate

omocianine — trihydrogéno-2-[(1*E*,3*E*,5*E*)-7-[(2*E*)-3,3-diméthyl-5-sulfonato-1-(2-sulfonatoéthyl)-1,3-dihydro-2*H*-indol-2-ylidène]-4-méthylhepta-1,3,5-triényl]-3,3-diméthyl-1-(2-sulfonatoéthyl)-3*H*-indolium-5-sulfonate

omocianina — trihidrógeno-2-[(1*E*,3*E*,5*E*)-7-[(2E)-3,3-dimetil-5-sulfonato-1-(2-sulfonatoetil)-1,3-dihidro-2*H*-indol-2-ilideno]-4-metilhepta-1,3,5-trienil]-3,3-dimetil-1-(2-sulfonatoetil)-3*H*-indolio-5-sulfonato

$C_{32}H_{38}N_2O_{12}S_4$



peliglitazarum

peliglitazar — *N*-[(4-methoxyphenoxy)carbonyl]-*N*-[(1*S*)-1-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}ethyl]glycine

péliglitazar — acide [[(4-méthoxyphénoxy)carbonyl][(1*S*)-1-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]phényl]éthyl]amino]acétique

peliglitazar — ácido [[(4-metoxifenoxi)carbonil][(1*S*)-1-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]fenil]etil]amino]acético

$C_{30}H_{30}N_2O_7$



pemaglitazarum

pemaglitazar	(2*S*)-4-[(2-methylphenyl)sulfanyl]-2-[4-(trifluromethyl)phenoxy]= butanoic acid
pémaglitazar	(-)-acide (2*S*)-4-[(2-méthylphényl)sulfanyl]-2-[4-(trifluorométhyl)= phénoxy]butanoïque
pemaglitazar	(-)-ácido (2*S*)-4-[(2-metilfenil)sulfanil]-2-[4-(trifluorometil)fenoxi]= butanoico

$C_{18}H_{17}F_3O_3S$



perflisobutanum

perflisobutane	1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane
perflisobutane	1,1,1,2,3,3,3-heptafluoro-2-(trifluorométhyl)propane
perflisobutano	1,1,1,2,3,3,3-heptafluoro-2-(trifluorometil)propano

C_4F_{10}



piclozotanum

piclozotan	3-chloro-4-[4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-1'-yl)butyl]-1,4-benzoxazepin-5(4*H*)-one
piclozotan	3-chloro-4-[4-(3',6'-dihydro-2,4'-bipyridinyl-1'(2'*H*)-yl)butyl]-1,4-benzoxazépin-5(4*H*)-one
piclozotán	3-cloro-4-[4-(3',6'-dihidro-2,4'-bipiridinil-1'(2'*H*)-il)butil]-1,4-benzoxazepin-5(4*H*)-ona

$C_{23}H_{24}ClN_3O_2$



pralatrexatum

pralatrexate — *N*-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid

pralatrexate — acide (2*S*)-2-[[4-[(1*RS*)-1-[(2,4-diaminoptéridin-6-yl)méthyl]but-3-ynyl]benzoyl]amino]pentanedioïque

pralatrexato — ácido (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-il)metil]but-3-inil]benzoil]amino]pentanodioico

$C_{23}H_{23}N_7O_5$



and epimer at C*
et l'épimère en C*
y el epímero en C*

radoterminum

radotermin — growth differentiation factor 5 (human), homodimer

radotermine — facteur 5 humain de différenciation de la croissance, homodimère produit par *E. coli*

radotermina — factor 5 humano de diferenciación del crecimiento homodímero producido por *E. coli*

$C_{1184}H_{1844}N_{330}O_{350}S_{22}$

raxibacumabum

raxibacumab — immunoglobulin G1, anti-(anthrax protective antigen) (human monoclonal PA heavy chain), disulfide with human monoclonal PA λ-chain, dimer

raxibacumab — immunoglobuline G1, anti-(antigen protecteur de l'anthrax), dimère du disulfure entre la chaine lourde et la chaîne λ de l'anticorps monoclonal humain PA

raxibacumab — inmunoglobulina G1, anti-(antígeno protector del antrax), dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano PA

$C_{6320}H_{9794}N_{1702}O_{1998}S_{42}$

rimeporidum

rimeporide — *N*-(aminoiminomethyl)-4,5-bis(methanesulfonyl)-2-methylbenzamide

riméporide — *N*-carbamimidoyl-2-méthyl-4,5-bis(méthylsulfonyl)benzamide

rimeporida — *N*-carbamimidoil-2-metil-4,5-bis(metilsulfonil)benzamida

$C_{11}H_{15}N_3O_5S_2$



saxagliptinum

saxagliptin — (1*S*,3*S*,5*S*)-2-{(2*S*)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptine — (1*S*,3*S*,5*S*)-2-[(2*S*)-amino(3-hydroxytricyclo[3.3.1.1^{3,7}]déc-1-yl)=acétyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptina — (1*S*,3*S*,5*S*)-2-[(2*S*)-amino(3-hidroxitriciclo[3.3.1.1^{3,7}]dec-1-il)acetil]-2-azabiciclo[3.1.0]hexano-3-carbonitrilo

$C_{18}H_{25}N_3O_2$



seliciclibum

seliciclib — (2*R*)-2-{[6-benzylamino-9-(propan-2-yl)-9*H*-purin-2-yl]amino}butan-1-ol

séliciclib — (-)-(2*R*)-2-[[6-(benzylamino)-9-(1-méthyléthyl)-9*H*-purin-2-yl]amino]=butan-1-ol

seliciclib — (-)-(2*R*)-2-[[6-(bencilamino)-9-(1-metiletil)-9*H*-purin-2-il]amino]butan-1-ol

$C_{19}H_{26}N_6O$



sugammadexum

sugammadex — cyclooctakis-(1→4)-[6-*S*-(2-carboxyethyl)-6-thio-α-D-glucopyranosyl]

sugammadex — cyclooctakis-(1→4)-[6-*S*-(2-carboxyéthyl)-6-thio-α-D-glucopyranosyl]

sugammadex — ciclooctakis-(1→4)-[6-S-(2-carboxietil)-6-tio-α-D-glucopiranosil]

$C_{72}H_{112}O_{48}S_8$



talabostatum

talabostat — {(2*R*)-1-[(2*S*)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl}boronic acid

talabostat — acide [(2*R*)-1-[(2*S*)-2-amino-3-méthylbutanoyl]pyrrolidin-2-yl]= boronique

talabostat — ácido [(2*R*)-1-[(2*S*)-2-amino-3-metilbutanoil]pirrolidin-2-il]borónico

$C_9H_{19}BN_2O_3$



talactoferrinum alfa

talactoferrin alfa — lactoferrin (recombinant human LF00)

talactoferrine alfa — [11-L-thréonine,29-L-arginine]lactotransferrine humaine produite par *Aspergillus niger* var. *awamori*

talactoferrina alfa — [11-L-treonina,29-L-arginina]lactotransferrina humana producida por *Aspergillus niger* var. *awamori*

$C_{3345}H_{5215}N_{963}O_{1015}S_{37}$ (peptide)

GRRRRSVQWC TVSQPEATKC FQWQRNMRRV RGPPVSCIKR
DSPIQCIQAI AENRADAVTL DGGFIYEAGL APYKLRPVAA
EVYGTERQPR THYYAVAVVK KGGSFQLNEL QGLKSCHTGL
RRTAGWNVPI GTLRPFLNWT GPPEPIEAAV ARFFSASCVP
GADKGQFPNL CRLCAGTGEN KCAFSSQEPY FSYSGAFKCL
RDGAGDVAFI RESTVFEDLS DEAERDEYEL LCPDNTRKPV
DKFKDCHLAR VPSHAVVARS VNGKEDAIWN LLRQAQEKFG
KDKSPKFQLF GSPSGQKDLL FKDSAIGFSR VPPRIDSGLY
LGSGYFTAIQ NLRKSEEEVA ARRARVVWCA VGEQELRKCN
QWSGLSEGSV TCSSASTTED CIALVLKGEA DAMSLDGGYV
YTAGKCGLVP VLAENYKSQQ SSDPDPNCVD RPVEGYLAVA
VVRRSDTSLT WNSVKGKKSC HTAVDRTAGW NIPMGLLFNQ
TGSCKFDEYF SQSCAPGSDP RSNLCALCIG DEQGENKCVP
NSNERYYGYT GAFRCLAENA GDVAFVKDVT VLQNTDGNNN
EAWAKDLKLA DFALLCLDGK RKPVTEARSC HLAMAPNHAV
VSRMDKVERL KQVLLHQQAK FGRNGSDCPD KFCLFQSETK
NLLFNDNTEC LARLHGKTTY EKYLGPQYVA GITNLKKCST
SPLLEACEFL RK

* glycosylation site
* sites de glycosylation
* posición de glicosilación

talaglumetadum

talaglumetad — (1*S*,2*S*,5*R*,6*S*)-2-[(2*S*)-2-aminopropanamido]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid

talaglumétad — acide (1*S*,2*S*,5*R*,6*S*)-2-[[(2*S*)-2-aminopropanoyl]amino]=bicyclo[3.1.0]hexane-2,6-dicarboxylique

talaglumetad — ácido (1*S*,2*S*,5*R*,6*S*)-2-[[(2*S*)-2-aminopropanoil]amino]=biciclo[3.1.0]hexano-2,6-dicarboxílico

$C_{11}H_{16}N_2O_5$



tanogitranum

tanogitran — *N*-[(2*R*)-2-{2-[(4-carbamimidoylanilino)methyl]-1-methyl-1*H*-benzimidazol-5-yl}-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl]glycine

tanogitran — acide [[(1*R*)-1-[2-[[(4-carbamimidoylphényl)amino]méthyl]-1-méthyl-1*H*-benzimidazol-5-yl]-1-méthyl-2-oxo-2-(pyrrolidin-1-yl)éthyl]=amino]acétique

tanogitrán — ácido [[(1*R*)-1-[2-[[(4-carbamimidoilfenil)amino]metil]-1-metil-1*H*-bencimidazol-5-il]-1-metil-2-oxo-2-(pirrolidin-1-il)etil]amino]=acético

$C_{25}H_{31}N_7O_3$



tefibazumabum

tefibazumab — immunoglobulin G1, anti-(*Staphylococcus aureus* protein ClfA (clumping factor A)) (human-*Mus musculus* monoclonal Aurexis heavy chain), disulfide with human-*Mus musculus* monoclonal Aurexis κ-chain, dimer

téfibazumab — immunoglobuline G1, anti-(protéine ClfA (facteur A d'agrégation) de *Staphylococcus aureus*) dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal *Mus-musculus* Aurexis humanisé

tefibazumab — inmunoglobulina G1, anti-(proteína ClfA (factor A de agregación) de *Staphylococcus aureus*) dimero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano *Mus-musculus* Aurexis

$C_{6548}H_{10122}N_{1730}O_{2034}S_{44}$

temsirolimusum

temsirolimus — (1*R*,2*R*,4*S*)-4-{(2*R*)-2-(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3*H*-23,27-epoxypyrido[2,1-*c*][1,4]=oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

temsirolimus — 3-hydroxy-2-(hydroxyméthyl)-2-méthylpropanoate de (1*R*,2*R*,4*S*)-4-[(2*R*)-2-[(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tétracosahydro-23,27-époxy-3*H*-pyrido[2,1-*c*][1,4]oxazacyclohentriacontin-3-yl]propyl]-2-méthoxycyclohexyle

temsirolimus — 3-hidroxi-2-(hidroximetil)-2-metilpropanoato de (1*R*,2*R*,4*S*)-4-[(2*R*)-2-[(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahidro-23,27-epoxi-3*H*-pirido[2,1-*c*][1,4]oxazaciclohentriacontin-3-il]propil]-2-metoxiciclohexilo

$C_{56}H_{87}NO_{16}$



tetomilastum

tetomilast	6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid
tétomilast	acide 6-[2-(3,4-diéthoxyphényl)thiazol-4-yl]pyridine-2-carboxylique
tetomilast	ácido 6-[2-(3,4-dietoxifenil)tiazol-4-il]piridina-2-carboxílico

$C_{19}H_{18}N_2O_4S$



thrombomodulinum alfa

thrombomodulin alfa	1-498-thrombomodulin (human clone TMP26/TMJ1 protein moiety reduced)
thrombomoduline alfa	[473-valine]précurseur de la thrombomoduline humaine-(19-516)-peptide (protéine soluble)
trombomodulina alfa	[473-valina]precursor de la trombomodulina humana-(19-516)-péptido (proteína soluble)

$C_{2230}H_{3357}N_{633}O_{718}S_{50}$



* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Non Proprietary Names (Prop. INN): List 92
Dénominations communes internationales proposées (DCI Prop.): Liste 92
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 92
(WHO Drug Information, Vol. 18, No. 4, 2004)

	suprimáse	*insértese*
p. 351	**temserolimusum**	**temsirolimusum**
	temserolimus	temsirolimus

p. 354 **thrombomodulinum alfa**

thrombomodulin alfa
thrombomoduline alfa
trombomodulina alfa

replace the graphic formula by the following:
remplacer la formule développée par:
sustitúyase la fórmula desarrollada por:



* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

Recommended International Nonproprietary Names (Rec. INN): List 16
Dénominations communes internationales recommandées (DCI Rec.): Liste 16
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 16
(WHO Drug Information, Vol. 30, No. 10, 1976)

p. 6 **nosiheptidum**

nosiheptide
nosiheptide
nosiheptida

replace the molecular formula by the following:
remplacer la formule brute par:
sustitúyase la fórmula empírica por:

$C_{51}H_{43}N_{13}O_{12}S_6$

Recommended International Nonproprietary Names (Rec. INN): List 34
Dénominations communes internationales recommandées (DCI Rec.): Liste 34
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34
(WHO Drug Information, Vol. 8, No. 3, 1994)

	suprimase	*insértese*
p. 5	bosentano	bosentán

Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 252	*suprimáse* esoxybutynina	*insértese* esoxibutinina
p. 258	*suprimáse* ramelteòn	*insértese* ramelteón

Recommended International Nonproprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 74 **dasantafilum**

dasantafil — *replace the chemical name by the following:*

7-(3-bromo-4-methoxyphenylmethyl)-1-ethyl-8-{[(1*R*,2*R*)-2-hydroxycyclopentyl]=amino}-3-(2-hydroxyethyl)-3,7-dihydro-1*H*-purine-2,6-dione

p. 75 **deluceminum**

delucemine — *replace the molecular formula by the following:*
délucémine — *remplacer la formule brute par:*
delucemina — *sustitúyase la fórmula empírica por:*

$C_{16}H_{17}F_2N$

p. 84 **maravirocum**

maraviroc — *replace the chemical name by the following:*

4,4-difluoro-*N*-[(1*S*)-3-{(1*R*,3*s*,5*S*)-3-[3-methyl-5-(propan-2-yl)-4*H*-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexanecarboxamide

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.